ArticleJournal of neuro-oncology2005
CHEK2 mutations in primary glioblastomas.
Article in Journal of neuro-oncology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Explainable Machine Learning Models for Glioma Subtype Classification and Survival Prediction.Cancers · 2025Article
- Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.Molecular cancer · 2025Review
- Prevalence of pathogenic germline variants in adult-type diffuse glioma.Neuro-oncology practice · 2023Article
- Article
- The First Case Report of a Patient With Oligodendroglioma HarboringFrontiers in genetics · 2022Article
- IsBMJ case reports · 2020Article
- Article
- Exploration of Involved Key Genes and Signaling Diversity in Brain Tumors.Cellular and molecular neurobiology · 2018Review
- Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer.Neuro-oncology · 2014Article
- CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer.Prostate cancer · 2014Review
- Aberrant signaling pathways in glioma.Cancers · 2011Article
- Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas.Cancer cell · 2010Article
- Role of CHK2 in cancer development.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2008Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.